Trial Profile
A phase II, multicenter, single-arm study of Herceptin (trastuzumab) in subjects with HER2-overexpressing colorectal cancer who have not received prior cytotoxic chemotherapy for metastatic disease
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2005
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 13 Dec 2005 New trial record.